Cellectis SA is a clinical stage biotechnology company that focuses on gene editing to create allogeneic CAR T cell product candidates for immuno oncology and gene therapy. The company was founded in 2000 and has built a proprietary gene editing platform based on TALEN nucleases and PulseAgile electroporation technology. This platform enables precise insertion deletion or repair of DNA sequences in T cells taken from healthy donors. By editing these cells Cellectis creates universal CAR T cells that express chimeric antigen receptors targeting antigens such as CD19 CD20 CD22 CD70 and BCMA. The edited T cells are designed to lack functional T cell receptors to reduce the risk of graft versus host disease and may also have knockouts of genes such as CD52 or beta2 microglobulin to improve persistence and resistance to lymphodepletion agents. Cellectis advances its own product candidates through clinical trials while also licensing its technology to partners including AstraZeneca Allogene Servier and Iovance Biotherapeutics. The company operates manufacturing sites in Raleigh North Carolina and Paris France to produce clinical and commercial scale CAR T cell products. Its strategy centers on advancing its proprietary UCART pipeline toward biologics license applications and establishing off the shelf therapies that can be stored distributed and administered globally. Through these activities Cellectis aims to address unmet medical needs in hematologic malignancies and solid tumors while leveraging its intellectual property to generate revenue from collaborations.

Revenue is generated primarily through licensing agreements with pharmaceutical and biotechnology partners. These agreements typically involve upfront payments development milestone payments sales milestone payments and tiered royalties on net sales of products commercialized by the partners. Cellectis has an agreement with AstraZeneca that provides upfront payments of twenty five million dollars and potential milestone payments ranging from eighty million to two hundred fifty three million dollars per target plus royalties in the mid single to low double digit percentages. The collaboration with Allogene includes an exclusive worldwide license for fifteen selected targets with aggregate milestone payments of up to one hundred eighty five million dollars and royalties in the high single digit range. Under the Servier license agreement Cellectis is eligible to receive low double digit royalties on annual net sales of commercialized products and additional milestone payments that could total up to three hundred forty million dollars subject to arbitration outcomes. The partnership with Iovance Biotherapeutics provides development regulatory and sales milestone payments as well as royalty payments based on net sales of TALEN modified tumor infiltrating lymphocyte products. Cellectis also receives option exercise fees and reimbursement of research costs under certain collaboration frameworks. While the company’s product candidates are still in clinical stages and not yet generating product sales the licensing model provides a steady stream of cash inflows that support ongoing research and development activities.

Cellectis occupies a distinct position in the allogeneic CAR T cell sector where it competes against both autologous and allogeneic therapy developers. Autologous competitors include Novartis with tisagenlecleucel Kite Pharma with axicabtagene ciloleucel Bristol Myers Squibb with lisocabtagene maraleucel Janssen with ciltacabtagene autoleucel and bluebird bio with idecabtagene vicleucel. Other allogeneic players consist of Fate Therapeutics CRISPR Therapeutics Precision BioSciences Mustang Bio and Atara Biotherapeutics. Cellectis differentiates itself through its TALEN nuclease platform which offers high precision and efficiency in targeting DNA sequences. The company’s PulseAgile electroporation system supports high viability of edited T cells and is suited for large scale manufacturing processes. Its intellectual property portfolio includes numerous patents covering gene editing methods electroporation CAR designs gene knockouts and manufacturing techniques providing a strong barrier to entry. Cellectis operates two manufacturing facilities that meet GMP standards one in Raleigh North Carolina and one in Paris France which enables it to produce clinical and commercial batches of its UCART product candidates. Clinical progress includes Phase 2 trials for lasme cel targeting CD22 in B cell acute lymphoblastic leukemia and eti cel targeting CD20 and CD22 in non Hodgkin lymphoma as well as licensed programs such as ALLO 501A and ALLO 316 in advanced testing. These technical manufacturing and intellectual property advantages allow Cellectis to pursue off the shelf therapies that could lower costs broaden patient access and improve safety compared with individualized autologous approaches.

The company’s customers are primarily its collaboration partners which include AstraZeneca Allogene Servier and Iovance Biotherapeutics. These entities license Cellectis gene editing technology to develop their own product candidates targeting a range of hematologic and solid tumor indications. In return for the licenses Cellectis receives upfront payments development milestone payments sales milestone payments and royalty payments based on the net sales of the partnered products. The collaborations also provide Cellectis with validation of its technology platform and access to additional expertise and resources through joint research efforts. While the firm’s ultimate end users will be hospitals and patients that receive its allogeneic CAR T cell therapies the current revenue base is derived from these biopharmaceutical relationships. Cellectis maintains clinical trial sites at major medical centers such as MD Anderson Cancer Center and other institutions where its product candidates are being evaluated. As its therapies advance toward regulatory approval the company expects to expand its customer base to include healthcare providers and payers that will administer and reimburse its off the shelf treatments.